About Seer, Inc.

Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.

Our novel Proteograph™ platform allows for the first-ever generation of proprietary proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, and affording comprehensive insights to deliver first-in-class liquid biopsy products with a goal of achieving very early disease detection.

We are advancing a portfolio of first-in-class liquid biopsy products to detect disease at early, pre-symptomatic stages to drive earlier treatment and improved outcomes.  We will also seek to establish strategic collaborations with industry partners to leverage our Proteograph platform to impact drug discovery and development.

 
 

investors

Our Science

The Promise of Proteomics

Powerful, Untapped Disease Insights

The human proteome comprises more than 20,000 proteins.  Proteins carry out nearly every function of the human body.  The proteome can give us powerful insights into the presence and progression of disease that could be used by clinicians to drive treatment decisions. But, until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes.

Molecular Information to Unlock Early Disease Detection

While genomic data has represented a massive step forward in helping us understand and more precisely treat disease, it has shown limited ability to detect early stage disease and track disease progression.  Proteomics reveals the relatively much larger body of data about health, including the future of health, and may hold the key to unlocking the elusive goal of early disease detection.

Translating Promise Into Reality

The promise of proteomics to yield critical disease data has long been known. But, until now, there have been major technical and economic barriers to broad-scale proteomics analyses. A primary obstacle has been the difficulty in managing the huge dynamic range of protein concentrations, with variations of 10-12 orders of magnitude from the most to the least abundant proteins in the plasma and other biologic fluids.

Research approaches have been developed to broadly analyze proteins across this dynamic range, but these approaches can take days to weeks to analyze a single sample. Our proprietary Proteograph technology platform is designed to overcome these challenges and deliver on the promise of proteomics to enable early, pre-symptomatic detection of cancer, neurological, and other diseases.

Novel Technology and Approach

Our Proteograph platform is designed to deliver proprietary proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, enabling first-in-class liquid biopsy products for early disease detection.

Proteograph
Platform
Individual biomolecular fingerprints

  • Proprietary combination of novel biosensors that sample the proteome
  • Captures multiple data points for thousands of proteins from a single sample with high sensitivity and specificity, including unique proteins and protein-to-protein interactions
  • Yields broad and deep biomolecular fingerprint of health status and disease for each patient
Early Disease
Detection
Robust portfolio of liquid biopsy products

  • Translate disease-specific, population-based data into real-world healthcare solutions
  • Advance a robust portfolio of products to enable early, pre-symptomatic detection of specific diseases and help guide treatment decision
  • With multiple ongoing clinical studies underway, our initial focus areas are oncology and neurology
Accelerate
R&D
Partnered product development

  • Strategically partner to apply the Proteograph platform for biomarker discovery, target identification, and accelerating clinical development

Collaborations to Enrich Data Sets

We will work with industry, government, and leading academic institutions to complement our activities in building internal data sets by accessing highly phenotyped patient samples.

Current collaborations

Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center (oncology patient samples)

Brigham and Women’s Hospital (neurology patient samples)

Rich Information from Proteograph Platform

1

1

 

Detect subtle changes in the proteome when comparing healthy to disease states

2

2

Broadly sample the proteome for comprehensive analysis across the range of protein concentrations

3

3

Unveil biological insights from protein interactions and protein structural changes

 

News

Press Release – December 17, 2018

  Seer Debuts with Proprietary Proteomics Platform to Enable Early Detection of Cancer and Neurological Diseases   -Proteograph™ platform yields highly accurate, broad-scale information on health status and disease not previously possible-  –Advancing pipeline of first-in-class […]

0 comments

Leadership

Seer’s leadership and clinical and scientific advisers include a multidisciplinary group of renowned experts in proteomics, data sciences, nanotechnology, and precision medicine.

  • Omid Farokhzad, M.D.

    Chief Executive Officer

    Omid Farokhzad, M.D.

    Chief Executive Officer

    • Philip Ma, Ph.D.

      Chief Business Officer and President

      Philip Ma, Ph.D.

      Chief Business Officer and President

      • John Blume, Ph.D.

        VP, Research

        John Blume, Ph.D.

        VP, Research

        • Bill Manning, Ph.D.

          VP, Product Development

          Bill Manning, Ph.D.

          VP, Product Development

          • Greg Troiano, M.S. Eng.

            VP, Technology and Chief Engineer

            Greg Troiano, M.S. Eng.

            VP, Technology and Chief Engineer

            • Lyndal Hesterberg, Ph.D.

              Seer’s Distinguished Fellow

              Lyndal Hesterberg, Ph.D.

              Seer’s Distinguished Fellow

              • Lyssa Friedman, M.P.A.

                Head of Clinical Operations

                Lyssa Friedman, M.P.A.

                Head of Clinical Operations

                • John Schembri

                  Controller

                  John Schembri

                  Controller

                  • Omid Farokhzad, M.D.

                    Chief Executive Officer

                    Omid Farokhzad, M.D.

                    Chief Executive Officer

                    • David Hallal

                      Former Chief Executive officer at Alexion Pharmaceuticals

                      David Hallal

                      Former Chief Executive officer at Alexion Pharmaceuticals

                      • Robert Langer, Sc.D.

                        Institute Professor - Massachusetts Institute of Technology

                        Robert Langer, Sc.D.

                        Institute Professor - Massachusetts Institute of Technology

                        • Terry McGuire

                          Founding Partner of Polaris Partners

                          Terry McGuire

                          Founding Partner of Polaris Partners

                          • David Singer

                            Managing Partner at Maverick Ventures

                            David Singer

                            Managing Partner at Maverick Ventures

                            • Robert Langer, Sc.D.

                              Chairman of Scientific Advisory Board

                              Robert Langer, Sc.D.

                              Chairman of Scientific Advisory Board

                              • Vivek Farias, Ph.D.

                                Chair of Data Committee

                                Vivek Farias, Ph.D.

                                Chair of Data Committee

                                • Philip Kantoff, M.D.

                                  Chair of Clinical Committee

                                  Philip Kantoff, M.D.

                                  Chair of Clinical Committee

                                  • Mostafa Ronaghi, Ph.D.

                                    Chair of Technology Committee

                                    Mostafa Ronaghi, Ph.D.

                                    Chair of Technology Committee

                                    • Erwin Böttinger, M.D.

                                      Professor of the Digital Engineering Faculty of HPI

                                      Erwin Böttinger, M.D.

                                      Professor of the Digital Engineering Faculty of HPI

                                      • Steve Carr, PH.D.

                                        Senior Director of Proteomics at Broad Institute of MIT and Harvard

                                        Steve Carr, PH.D.

                                        Senior Director of Proteomics at Broad Institute of MIT and Harvard

                                        • Charles Cantor, Ph.D.

                                          Emeritus Professor at Boston University

                                          Charles Cantor, Ph.D.

                                          Emeritus Professor at Boston University

                                          • Bradley Hyman, M.D., Ph.D.

                                            John B. Penny Professor of Neurology at Harvard Medical School

                                            Bradley Hyman, M.D., Ph.D.

                                            John B. Penny Professor of Neurology at Harvard Medical School

                                            • Wolfgang Parak, Ph.D.

                                              Professor of Physics and Chemistry at University of Hamburg

                                              Wolfgang Parak, Ph.D.

                                              Professor of Physics and Chemistry at University of Hamburg

                                              • Ralph Weissleder, M.D.

                                                Thrall Professor of Radiology at Harvard Medical School

                                                Ralph Weissleder, M.D.

                                                Thrall Professor of Radiology at Harvard Medical School

                                                Careers

                                                Life at Seer

                                                Seer is rapidly growing its team with accomplished individuals.  The Seer team is made up of talented and driven people who are united by their passion for extending patients’ lives through the early detection and treatment of devastating diseases.  We value a collaborative environment where employees are empowered to excel.

                                                 

                                                EMPLOYEE EXPERIENCE

                                                I really feel that I have a voice at Seer. The company leaders, my colleagues and I are very much connected.

                                                Hongwei Xia
                                                Scientist

                                                EMPLOYEE EXPERIENCE

                                                Seer is all about learning; the leaders constantly motivate us to challenge common wisdom and solve problems more effectively.

                                                Shadi Roshdiferdosi
                                                Associate Scientist

                                                EMPLOYEE EXPERIENCE

                                                Seer is young, but we already have the foundations for an amazing culture – a dedicated and diverse team, passionate about making a difference for patients!

                                                Lily Paloma
                                                Human Resources & Office Manager

                                                EMPLOYEE EXPERIENCE

                                                I really enjoy collaborating with my scientist colleagues. The whole team tackles challenges together, and we’re much greater than the sum of our parts.

                                                Lyssa Friedman
                                                Head of Clinical Operations

                                                EMPLOYEE EXPERIENCE

                                                I am encouraged to push the boundaries of my own technical knowledge just as Seer pushes the boundaries in proteomics.

                                                Marwin Ko
                                                Associate Data Scientist

                                                Open Positions

                                                See open positions at Seer

                                                 

                                                For more information, contact careers@seer.bio

                                                Contact

                                                +1-650-453-0000, info@seer.bio
                                                170 Harbor Way, South San Francisco, CA 94080

                                                SEE MAP